Latest Articles

Publication Date
Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer - Dana-Farber Cancer Institute

Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer Dana-Farber Cancer Institute

Published: Oct. 21, 2025, 9 a.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace

Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer BioSpace

Published: Oct. 21, 2025, 5:15 a.m.
KEYNOTE-755 Confirms Broad Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer - Pharmacy Times

KEYNOTE-755 Confirms Broad Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer Pharmacy Times

Published: Oct. 21, 2025, 3:34 a.m.
IL-6 Inhibits Invasion in a Murine Model of Endometriosis.

Endometriosis is a gynecological inflammatory disorder characterized by the presence of endometrial tissue outside of the uterus. It affects 10-15% of reproductive aged women, causing pelvic pain and infertility. Existing …

Published: Oct. 21, 2025, midnight
'En bloc' peritoneal mesometrial resection (PMMR) and pelvic targeted compartmental lymphadenectomy (TCL) for management of patients with endometrial cancer - feasibility and safety study of a 'new kid on the block' in robotic surgery.

Robotic Peritoneal Mesometrial Resection and Targeted Compartmental Lymphadenectomy (PMMR + TCL) is a procedure following Cancer Field Surgery concept for endometrial cancer (EC), enabling superior locoregional control without adjuvant irradiation. …

Published: Oct. 21, 2025, midnight
Pro-endometriosis macrophage release of IL-33 is key for endometriosis pain and lesion formation.

Endometriosis is a painful gynecological inflammatory disease affecting up to 10% of females. When released by sensory neurons, calcitonin gene-related peptide (CGRP) shapes immunity, a process known as neuroimmune communication. …

Published: Oct. 21, 2025, midnight
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal

Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal

Published: Oct. 20, 2025, 9:33 p.m.
Endometrial Ablation as a Safe Treatment for Adenomyosis-Related Abnormal Uterine Bleeding in Women with Cerebral Infarction: A Case Report - Frontiers

Endometrial Ablation as a Safe Treatment for Adenomyosis-Related Abnormal Uterine Bleeding in Women with Cerebral Infarction: A Case Report Frontiers

Published: Oct. 20, 2025, 9 p.m.
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer - Pulse 2.0

Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer Pulse 2.0

Published: Oct. 20, 2025, 3:54 p.m.
Faeth Therapeutics Raises $25 Million, Reports Phase 2 Results in Ovarian and Endometrial Cancer - Femtech Insider

Faeth Therapeutics Raises $25 Million, Reports Phase 2 Results in Ovarian and Endometrial Cancer Femtech Insider

Published: Oct. 20, 2025, 2:27 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!